Michael Hoffman - Onconova Therapeutics Insider

ONTX -- USA Stock  

USD 0.47  0.0194  3.96%

  Chairman
Mr. Michael B. Hoffman serves as Chairman of the Board of Onconova Therapeutics, Inc., since 2006. He is a member of the board of directors since December 2002. Since 2003, Mr. Hoffman was a managing director of Riverstone Holdings LLC, or Riverstone, where he is principally responsible for investments in power and renewable energy. Before joining Riverstone, Mr. Hoffman was senior managing director and head of the mergers and acquisitions advisory business of The Blackstone Group L.P., or Blackstone, where he also served on the firm principal group investment committee as well as its executive committee. Prior to joining Blackstone, Mr. Hoffman was managing director and cohead of the mergers and acquisitions department at Smith Barney, Harris Upham Co
Age: 66  Chairman Since 2006  MBA    
267-759-3680  http://www.onconova.com
Hoffman received his Bachelor and Master Degrees from Northwestern University and his M.B.A. from the Harvard Business School.

Michael Hoffman Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (65.92) % which means that it has lost $65.92 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (276.06) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 12 records

CHAIRMAN Since

Sol BarerEdge Therapeutics
2013
John AplinEndocyte
2011
Paul ManningDova Pharmaceuticals
2017
Patrick SoonShiongNantKwest
2015
Marc TessierLavignecDenali Therapeutics
N/A
Arnold OronskyDynavax Technologies Corporatio
2006
Yuen KamChina Cord Blood Corporation
2012
Steven GorlinNantKwest
2014
David MaddenDicerna Pharmaceuticals
2009
James HealyAuris Medical Holding AG
2013
Isaac BlechEdge Therapeutics
2013
Thomas MeyerAuris Medical Holding AG
N/A

Entity Summary

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania. Onconova Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 25 people.Onconova Therapeutics (ONTX) is traded on BATS Exchange in USA. It is located in PENNSYLVANIA U.S.A and employs 25 people. Onconova Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Onconova Therapeutics Leadership Team

Henry Bienen, Director
Ramesh Kumar, Co-Founder, CEO and President and Director
Anne VanLent, Director
Ajay Bansal, CFO and Secretary
Premkumar Reddy, Founder, Lead Scientific Advisor and Director
Jerome Groopman, Director
James Marino, Independent Director
Manoj Maniar, Sr. VP of Product Devel.
Thomas McKearn, President - Research and Development
Michael Hoffman, Chairman of the Board
Jack Stover, Director
Steven Fruchtman, Senior Vice President - Research and Development, Chief Medical Officer
Mark Guerin, Principal Accounting Officer and VP of Financial Planning and Accounting
Viren Mehta, Director

Stock Performance Indicators

Current Sentiment - ONTX

Onconova Therapeutics Investor Sentiment

Most of Macroaxis users are now bullish on Onconova Therapeutics. What is your perspective on investing in Onconova Therapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally take a look at Your Equity Center. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Search macroaxis.com